Inhibition of Friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Cancer Research

• Publication date

  1992-05-15

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 1581903
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice

  1991influential reference
• Monoclonal antibody-mediated tumor regression by induction of apoptosis.

  1989cited by this paper
• Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon.

  1989cited by this paper
• Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action.

  1988cited by this paper
• Wheat germ agglutinin-binding protein changes in highly malignant Friend leukemia cells metastasizing to the liver

  1988cited by this paper
• Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2.

  1988cited by this paper
• Interferon treatment markedly inhibits the development of tumor metastases in the liver and spleen and increases survival time of mice after intravenous inoculation of friend erythroleukemia cells

  1988influential reference
• Comparison of combinations of interferons with tumor specific and nonspecific monoclonal antibodies as therapy for murine B- and T-cell lymphomas.

  1988cited by this paper
• Anti‐tumor effects of interferon in mice injected with interferonsensitive and interferon‐resistant friend leukemia cells. VI. Adjuvant therapy after surgery in the inhibition of liver and spleen metastases

  1987cited by this paper
• Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.

  1987cited by this paper
• Methods for high frequency production of soluble antigen-specific hybridomas; specificities and affinities of the monoclonal antibodies obtained.

  1986cited by this paper
• Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma.

  1986cited by this paper
• Immunoprevention of Friend leukaemia virus-induced erythroleukaemia by vaccination with aggregated gp70.

  1986cited by this paper
• T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant.

  1986cited by this paper
• Syngeneic monoclonal anti-melanoma antibody that inhibits experimental lung metastasis of B16 melanoma.

  1986cited by this paper
• Friend murine leukemia virus and spleen focus-forming virus expression in highly malignant interferon-sensitive and interferon-resistant Friend leukemia cells.

  1986influential reference
• Monoclonal antibodies NORM-1 and NORM-2 induce more normal behavior of tumor cells in vitro and reduce tumor growth in vivo.

  1985cited by this paper
• Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors.

  1985cited by this paper
• Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside.

  1985cited by this paper
• Immunologic control of a retrovirus-associated murine adenocarcinoma. VII. Tumor cell destruction by macrophages and IgG2A.

  1985cited by this paper
• Immunologic control of a retrovirus-associated murine adenocarcinoma. VI. Augmentation of antibody-dependent killing following quantitative and qualitative changes in host peritoneal cells.

  1985cited by this paper
• Biologic and biochemical differences between in vitro and in vivo passaged friend erythroleukemia cells. II. Changes in cell surface glycoproteins associated with a highly malignant phenotype

  1984cited by this paper
• Biologic and biochemical differences between in vitro and in vivo passaged friend erythroleukemia cells. I. Tumorigenicity and capacity to metastasize

  1984cited by this paper
• Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.

  1983cited by this paper
• On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice.

  1983cited by this paper
• Use of monoclonal anti-gp70 antibodies to mimic the effects of the Rfv-3 gene in mice with Friend virus-induced leukemia.

  1983cited by this paper
• Monoclonal antibodies inhibit the adhesion of mouse B 16 melanoma cells in vitro and block lung metastasis in vivo.

  1983cited by this paper
• Evidence implicating L3T4 in class II MHC antigen reactivity; monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by cloned murine helper T lymphocyte lines.

  1983cited by this paper
• Antitumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend leukemia cells. I.

  1982cited by this paper
• Isolation of interferon-resistant variants of Friend erythroleukemia cells: effects of interferon and ouabain.

  1982cited by this paper
• Antitumor effects of interferon in mice injected with interferon‐sensitive and interferon‐resistant friend leukemia cells. II. Role of host mechanisms

  1982cited by this paper
• IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

  1982influential reference
• Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum.

  1981cited by this paper
• Immunotherapy of murine leukemias by monoclonal antibody. I. Effect of passively administered antibody on growth of transplanted tumor cells.

  1981cited by this paper
• Synthesis and phosphorylation of plasma membrane proteins of Friend erythroleukemia cells induced to differentiate.

  1981cited by this paper
• Mouse leukemia: therapy with monoclonal antibodies against a thymus differentiation antigen.

  1980influential reference
• Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody.

  1980cited by this paper
• Group-specific cytolytic antibody directed against the major glycoprotein (gp70) of murine leukemia viruses in serum of mice with dormant FLV infections.

  1979cited by this paper
• Tumor metastases and cell‐mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo

  1979cited by this paper
• Antigen-induced murine B-cell lymphomas. III. Passive anti-idiotype serum therapy and its combined effect with chemotherapy.

  1979cited by this paper
• Xenogeneic Monoclonal Antibodies to Mouse Lymphoid Differentiation Antigens *

  1979cited by this paper
• A Method for the Large Scale Production of Potent Interferon Preparations

  1974cited by this paper
• Passive immunotherapy of leukemia and other cancer.

  1971cited by this paper
• Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

  1970cited by this paper
• For April.

  1903cited by this paper

• Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity

  2018cites this paper
• Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?

  2017cites this paper
• Etude de l’immunité anti-tumorale à long-terme induite par traitement par un anticorps anti-CD20 de souris porteuses de tumeur

  2015influential citation
• Humoral immunity in the Friend retrovirus infection model

  2013cites this paper
• [The Janus face of monoclonal antibodies in oncology: passive immunity and vaccination].

  2013cites this paper
• Humoral immunity in the Friend retrovirus infection model

  2012cites this paper
• Modulation of tumor immunity by therapeutic monoclonal antibodies

  2011cites this paper
• Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.

  2010cites this paper
• Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response.

  2010cites this paper
• The antitumor effects of interferon: a personal history.

  2007cites this paper
• Potential uses of interferon α2 as adjuvant therapy in cancer

  1995cites this paper
• IFN-alpha 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice.

  1995cites this paper
• Synthetic hormone/growth factor subunit vaccine with application to antifertility and cancer.

  1995cites this paper
• Potential uses of interferon alpha 2 as adjuvant therapy in cancer.

  1995cites this paper
• IFN‐α1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice

  1995cites this paper
• Characterization of brain and bone-metastasizing clones selected from an ethylnitrosourea-induced rat mammary carcinoma

  1994cites this paper
• Pharmaceutical applications

  1992cites this paper